HEK293-VEGFR2 Cells

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.

HEK293-VEGFR2 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk-1), a receptor tyrosine kinase that serves as a principal mediator of VEGF-driven angiogenic signaling. VEGFR2 is primarily expressed on endothelial cells and plays essential roles in vascular development, endothelial cell proliferation, migration, permeability, and survival through activation of downstream pathways including MAPK/ERK, PI3K/AKT, PLCγ, and SRC family signaling cascades. Dysregulated VEGFR2 signaling contributes to tumor angiogenesis, inflammatory vascular remodeling, and pathological neovascularization, making the receptor a major target in oncology and vascular disease therapeutics.

HEK293-VEGFR2 cells are widely used in angiogenesis research and drug discovery for characterization of VEGFR2-targeted monoclonal antibodies, tyrosine kinase inhibitors, ligand traps, bispecific antibodies, and anti-angiogenic biologics. The stable recombinant expression system supports quantitative evaluation of VEGF ligand binding, receptor phosphorylation, downstream signaling activation, receptor internalization, and inhibitor potency. These cells are also commonly employed in reporter assays, flow cytometry-based binding studies, kinase activity assays, and high-throughput therapeutic screening workflows. Because HEK293 cells support robust recombinant protein expression and efficient propagation, they provide a reliable platform for standardized VEGFR2 assay development and mechanistic signaling studies.